Plaque Psoriasis Market Research
What is Plaque Psoriasis?
Plaque Psoriasis (PSO) is an autoimmune disease that causes raised, scaly patches called plaques on your skin that are commonly itchy or painful. While plaques may occur anywhere on the body, they most often occur on the elbows, knees, scalp and back. Currently, the exact cause for PSO is unknown, but the body’s immune system and genetics can play a significant role in its development.
Treatment options for patients with plaque psoriasis include topicals, phototherapy, oral treatments and biologics. While it is not a fully curable disease, these treatment options can significantly help to improve symptoms.
Spherix Global Insights – Dermatology – Plaque Psoriasis
Spherix Global Insights’ Dermatology therapeutic team is a leading provider of independent syndicated plaque psoriasis market research, insights, business intelligence & advisory services.
Spherix’s Dermatology team covers numerous studies publishing this year in their RealTime Dynamix™, Launch Dynamix™, and Patient Chart Dynamix™ services including:
- RealTime Dynamix™: Plaque Psoriasis (US)
- RealTime Dynamix™: Plaque Psoriasis (EU5)
- Launch Dynamix™: Sotyktu (BMS) in Plaque Psoriasis (US)
- Launch Dynamix™: Vtama (Dermavant) in Plaque Psoriasis (US)
- Launch Dynamix™: Zoryve (Arcutis) in Plaque Psoriasis (US)
- Launch Dynamix™: Bimzelx (UCB) in Plaque Psoriasis (US)
- Launch Dynamix™: Sonelokimab (MoonLake/Merck) in Plaque Psoriasis (US)*
- Patient Chart Dynamix™: Biologic/Small Molecule Switching in Plaque Psoriasis (US)
* Pending drug approval
Spherix’s RealTime Dynamix™ service provides strategic guidance through quarterly or semiannual reports. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-hour team of experts.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products which includes for the first eighteen months of commercial availability, and quarterly deep dive reports includes promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Spherix’s Patient Chart Dynamix™ service includes patient level data detailing clinical and non-clinical patient demographics, along with rationale for treatment choices. It reveals real patient management patterns through rigorous analysis of large-scale patient chart audits.
Follow Spherix Dermatology on Social Media
Follow us for dermatology industry news, insights & analysis:
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com